Microfluidic organoids-on-a-chip: The future of human models

Saorin, Gloria; Caligiuri, Isabella; Rizzolio, Flavio

doi:10.1016/j.semcdb.2022.10.001

Cited by 66 publications

(30 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microfluidic technology combined with organoids has the power to close the gap in the complexity of the human body ( Duzagac et al, 2021 ; Saorin et al, 2022 ). In a microfluidic organoid-on-a-chip platform, flow conditions, nutrient supply, shear stress, input-output, and geometry can be easily controlled, providing a way to carry out the experiment from a cellular to tissue and, finally, to organ levels ( Duzagac et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies

Cavarzerani

Caligiuri

Bartoletti

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

High-grade serous ovarian cancer (HGSOC) needs new technologies for improving cancer diagnosis and therapy. It is a fatal disease with few options for the patients. In this context, dynamic culture systems coupling with patient-derived cancer 3D microstructures could offer a new opportunity for exploring novel therapeutic approaches. In this study, we optimized a passive microfluidic platform with 3D cancer organoids, which allows a standardized approach among different patients, a minimum requirement of samples, multiple interrogations of biological events, and a rapid response. The passive flow was optimized to improve the growth of cancer organoids, avoiding the disruption of the extracellular matrix (ECM). Under optimized conditions of the OrganoFlow (tilting angle of 15° and an interval of rocking every 8 min), the cancer organoids grow faster than when they are in static conditions and the number of dead cells is reduced over time. To calculate the IC50 values of standard chemotherapeutic drugs (carboplatin, paclitaxel, and doxorubicin) and targeted drugs (ATRA), different approaches were utilized. Resazurin staining, ATP-based assay, and DAPI/PI colocalization assays were compared, and the IC50 values were calculated. The results showed that in the passive flow, the IC50 values are lower than in static conditions. FITC-labeled paclitaxel shows a better penetration of ECM under passive flow than in static conditions, and cancer organoids start to die after 48 h instead of 96 h, respectively. Cancer organoids are the last frontiers for ex vivo testing of drugs that replicate the response of patients in the clinic. For this study, organoids derived from ascites or tissues of patients with Ovarian Cancer have been used. In conclusion, it was possible to develop a protocol for organoid cultures in a passive microfluidic platform with a higher growth rate, faster drug response, and better penetration of drugs into ECM, maintaining the samples’ vitals and collecting the data on the same plate for up to 16 drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies

Cavarzerani

Caligiuri

Bartoletti

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, there has been a growing trend of combining spheroids and organoids with the on‐chip technology in the last few years. [ 13 ] Some articles reviewed the spheroids‐ and organoids‐on‐a‐chip technology based on the organ type, [ 14 ] specific biofunctions, [ 15 ] or specific microfluidic techniques, such as microfluidic droplets. [ 16 ] In this review, guided by the characteristics of on‐chip technology, we summarize the recent advances of spheroids and organoids on the chip contrastively.…”

Section: Overall Advances Of Spheroids and Organoids On A Microfluidi...mentioning

confidence: 99%

Advances in Spheroids and Organoids on a Chip

Fang

Chen

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Multicellular spheroids and organoids are promising in vitro 3D models in personalized medicine and drug screening. They replicate the structural and functional characteristics of human organs in vivo. Microfluidic technology and micro‐nano fabrication can fulfill the high requirement of the engineering approach in the growing research interest in spheroids and organoids. In this review, spheroids and organoids are comparatively introduced. Then it is illustrated how spheroids‐ and organoids‐on‐a‐chip technology facilitates their establishment, expansion, and application through spatial‐temporal control, mechanical cues modeling, high‐throughput analysis, co‐culture, multi‐tissue interactions, biosensing, and bioimaging integration. The potential opportunities and challenges in developing spheroids‐ and organoids‐on‐a‐chip technology are finally outlooked.

show abstract

“…Although the addition of ECs and/or vasculogenic growth factors such as VEGF-A help the construction of vascular networks in cardiac organoids to some extent, the absence of real blood perfusion represents one of the major hurdles in the current models. To solve this problem, there are currently ongoing various approaches using, for example, microfluidic chips and bioreactors [ 28 , 63 ]. Fifth, lack of an immune system (inflammatory cells) and a nervous system (neuron cells) in the current cardiac organoid models leads to incomplete recapitulation of interconnected developmental processes and features of the human native heart with non-cardiac lineages, although the latest report partially addressed this issue [ 50 ].…”

Section: Current Limitations and Future Perspectivesmentioning

confidence: 99%

“…Further, the limitations such as lack of standardization, reproducibility, and maturation in the current models of cardiac organoids, and the future perspectives on this promising technology are also discussed. In regards to topics of other in vitro 3D culture models, including various EHT models [ 16 , 26 ], a microfluidics/heart-on-a-chip [ 27 , 28 ], bioprinting [ 29 , 30 ], and electrospinning [ 31 , 32 ], the author asks readers to refer to the suggested reviews, respectively.…”

Section: Introductionmentioning

confidence: 99%

Recent Advances in Generation of In Vitro Cardiac Organoids

Sahara

2023

IJMS

View full text Add to dashboard Cite

Cardiac organoids are in vitro self-organizing and three-dimensional structures composed of multiple cardiac cells (i.e., cardiomyocytes, endothelial cells, cardiac fibroblasts, etc.) with or without biological scaffolds. Since cardiac organoids recapitulate structural and functional characteristics of the native heart to a higher degree compared to the conventional two-dimensional culture systems, their applications, in combination with pluripotent stem cell technologies, are being widely expanded for the investigation of cardiogenesis, cardiac disease modeling, drug screening and development, and regenerative medicine. In this mini-review, recent advances in cardiac organoid technologies are summarized in chronological order, with a focus on the methodological points for each organoid formation. Further, the current limitations and the future perspectives in these promising systems are also discussed.

show abstract

Microfluidic organoids-on-a-chip: The future of human models

Cited by 66 publications

References 89 publications

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies

3D dynamic cultures of HGSOC organoids to model innovative and standard therapies

Advances in Spheroids and Organoids on a Chip

Recent Advances in Generation of In Vitro Cardiac Organoids

Contact Info

Product

Resources

About